Reinmuth, N <br/><br/>
[A reduced TKI dosage is not associated with loss of activity in EGFR mutated NSCLC patients].  [electronic resource] 

 -  Pneumologie (Stuttgart, Germany)  Sep 2014 
 - 619-23 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1438-8790 
<br/><br/><label>Standard No.: </label>10.1055/s-0034-1377927  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--diagnosis<br/>Dose-Response Relationship, Drug<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Humans<br/>Lung Neoplasms--diagnosis<br/>Male<br/>Mutation--genetics<br/>Polymorphism, Single Nucleotide--genetics<br/>Protein Kinase Inhibitors--administration & dosage<br/>Treatment Outcome